Patient and neurologist preferences in the UK for relapsing–remitting multiple sclerosis treatments: findings from a discrete choice experiment

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options

(2020) Marcel F. Jonker et al.   MEDICAL DECISION MAKING

Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review

(2020) L.A. Visser et al.   Multiple Sclerosis and Related Disorders

Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis

(2019) Patrick Vermersch et al.   CLINICAL THERAPEUTICS

PND107 NEUROLOGIST AND PATIENT PREFERENCES IN MULTIPLE SCLEROSIS: UK AND US QUALITATIVE RESEARCH FINDINGS

(2019) T. Tencer et al.   VALUE IN HEALTH

Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art

(2019) Celeste Silveira et al.   Psychiatry Investigation

Deep gray matter volume loss drives disability worsening in multiple sclerosis

(2018) Arman Eshaghi et al.   ANNALS OF NEUROLOGY

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

(2017) Jonathan Q. Tran et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials

(2017) Cindy J. Nowinski et al.   Neurotherapeutics

Whole-brain atrophy

(2016) Christina J. Azevedo et al.   CURRENT OPINION IN NEUROLOGY

Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression

(2016) M. Moccia et al.   EUROPEAN JOURNAL OF NEUROLOGY

Further validation of the Multiple Sclerosis Self-Efficacy Scale

(2015) Chung-Yi Chiu et al.   DISABILITY AND REHABILITATION

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2015) F. H. Jacques et al.   NEUROLOGY

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

(2015) E.-W. Radue et al.   NEUROLOGY

The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects

(2013) A. Minagar et al.   NEUROLOGY

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

(2013) F. Reed Johnson et al.   VALUE IN HEALTH

Clinical correlates of grey matter pathology in multiple sclerosis

(2012) Dana Horakova et al.   BMC Neurology

Meningeal and cortical grey matter pathology in multiple sclerosis

(2012) Bogdan F Gh Popescu et al.   BMC Neurology

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

(2012) H Tedeholm et al.   Multiple Sclerosis Journal

Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: Results of a five-year brain MRI study

(2011) Omar Khan et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability

(2011) Stefan D Roosendaal et al.   Multiple Sclerosis Journal

Multiple sclerosis – candidate mechanisms underlying CNS atrophy

(2010) Volker Siffrin et al.   TRENDS IN NEUROSCIENCES

Evolving expectations around early management of multiple sclerosis

(2010) Ralf Gold et al.   Therapeutic Advances in Neurological Disorders